. Author manuscript; available in PMC: 2012 Mar 1.

Published in final edited form as: Brain Behav Immun. 2010 Nov 12;25(3):443–460. doi: 10.1016/j.bbi.2010.11.005

Table 2. Summary of the statistical analysis of the effects of DVC inactivation and LPS challenge on c-Fos expression in selected brain regions (2-way ANOVA)^*.

Brain region	main effects DVC bupivacaine		LPS treatment		Interaction LPS × DVC Bupiv
Brain region	F(1,13)	p	F(1,13)	p	F(1,13)	p
(behavior related)^**
CPu dm	16.3	0.0014	9.18	0.0097	23.86	0.0003
HPC d	7.26	0.018	4.87	0.046	4.79	0.0474
VTA r	13.9	0.0026	1.67	0.22	9.64	0.0084
(LPS-responsive)
PVN	4.76	0.048	18.41	0.0009	7.52	0.017
BSTov	6.34	0.026	26.44	0.0002	2.03	0.17
CEA	1.06	0.32	39.8	<.0001	5.85	0.031
PB el	4.58	0.052	56.21	<.0001	17.16	0.0012
VLM DBH cells	6.13	0.028	23.92	0.0003	5.74	0.032

significant effects (p < .05) are bolded. Statistics was performed on the total number of c-Fos-immunreactive profiles in each brain region, except for the DBH-labeled neurons in the VLM, which involved the percentage of the total number of DBH cells that expressed c-Fos.

^**

c-Fos expression in the TMV: see Gaykema et al., 2008.

Table 2. Summary of the statistical analysis of the effects of DVC inactivation and LPS challenge on c-Fos expression in selected brain regions (2-way ANOVA)*.

Table 2. Summary of the statistical analysis of the effects of DVC inactivation and LPS challenge on c-Fos expression in selected brain regions (2-way ANOVA)^*.